Sanj Patel, Kiniksa CEO (Kiniksa via YouTube)
Roche, Genentech place a $100M bet on fibrosis, nabbing PhII program from Kiniksa
As parent company Roche aims to secure a place in the allogeneic CAR-T therapy race, Genentech is spinning its own deal to jump into fibrosis …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
